Ann: MSB Reports Q3 Financial Results and Operational Highlights, page-280

I probably need to present a balanced arguement to your so called balanced arguement here.

The Downramp squad had egg on their faces when the four year mortality data was released, and demonstrated a mortality reduction of the likes that had never been obseved in any previous studys, or in any control group, or in any experimental groups for Sr AGvHD. You cannot find better survival data particularly in the higher risk groups.

Then there was more egg, when absolutely nothing happened as a result of several lawsuits that were apparently a sure thing to send the company broke.

Then even more egg when teh company released it's revised potency IL2rAlpha assay, which debunked the notion that the company would never have an adequate potency assay unless it had Interferon Gamma in it ( there was hundreds of paragraphs over weeks on that one.

Now rather than sticking with scientific rationale, the downramp squad has had to turn it's attention to non scientific things like.... Novartis walked away.... this other comnpany walked away.... that other company walked away.... if it doesn't get approved it's likely another pathway to bankruptcy

More egg - that last capital raise was massively oversubscribed - no shortage of people willing to fund it now or over the last 10 years, and with multiple products so close to the finish line, absolutley no indication at all that the situation is about to do a backflip.